252 related articles for article (PubMed ID: 18327587)
1. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
[TBL] [Abstract][Full Text] [Related]
2. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Orlowski RZ; Voorhees PM; Garcia RA; Hall MD; Kudrik FJ; Allred T; Johri AR; Jones PE; Ivanova A; Van Deventer HW; Gabriel DA; Shea TC; Mitchell BS; Adams J; Esseltine DL; Trehu EG; Green M; Lehman MJ; Natoli S; Collins JM; Lindley CM; Dees EC
Blood; 2005 Apr; 105(8):3058-65. PubMed ID: 15626743
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
Irvin WJ; Orlowski RZ; Chiu WK; Carey LA; Collichio FA; Bernard PS; Stijleman IJ; Perou C; Ivanova A; Dees EC
Clin Breast Cancer; 2010 Dec; 10(6):465-70. PubMed ID: 21147690
[TBL] [Abstract][Full Text] [Related]
8. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
10. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
11. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
[TBL] [Abstract][Full Text] [Related]
12. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Portnow J; Frankel P; Koehler S; Twardowski P; Shibata S; Martel C; Morgan R; Cristea M; Chow W; Lim D; Chung V; Reckamp K; Leong L; Synold TW
Cancer Chemother Pharmacol; 2012 Feb; 69(2):505-14. PubMed ID: 21850464
[TBL] [Abstract][Full Text] [Related]
14. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
Briasoulis E; Pentheroudakis G; Karavasilis V; Tzamakou E; Rammou D; Pavlidis N
Ann Oncol; 2004 Oct; 15(10):1566-73. PubMed ID: 15367419
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma.
Kusumoto S; Sunami K; Inagaki M; Iida S
Int J Hematol; 2015 Jun; 101(6):578-84. PubMed ID: 25749662
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B; Kmieciak M; Perkins EB; Bose P; Baz RC; Roodman GD; Stuart RK; Ramakrishnan V; Wan W; Peer CJ; Dawson J; Kang L; Honeycutt C; Tombes MB; Shrader E; Weir-Wiggins C; Wellons M; Sankala H; Hogan KT; Colevas AD; Doyle LA; Figg WD; Coppola D; Roberts JD; Sullivan D; Grant S
Clin Cancer Res; 2014 Nov; 20(22):5652-62. PubMed ID: 25248382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
